Communiqués PureTech Health plc

Actions

PRTC

GB00BY2Z0H74

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 17:35:08 02/09/2026			Varia. 5j.	Varia. 1 janv.
120,40 ^GBX	0,00%		0,00%	-3,68%

13/07	PureTech Health annonce l'administration du traitement au premier patient de l'essai de phase 3 de Celea	AN
13/07	PureTech Health : Celea Therapeutics lance un essai de phase finale pour son traitement de la fibrose pulmonaire idiopathique	MT

Communiqués

25/08	PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress	BU
25/08	Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress	BU
13/07	Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis	AQ
13/07	PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)	BU
02/07	Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)	BU
02/07	PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)	BU
10/06	PureTech Health: Results of Annual General Meeting	BU
09/06	PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers	BU
13/05	PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference	BU
29/04	PureTech Health : 2025 Annual Report and Accounts (optimized for printing)	PU
29/04	PureTech Health : Notice of Meeting for 2026 AGM	PU
29/04	PureTech Health : Proxy Form for 2026 AGM	PU
29/04	PureTech Health : Notice of Annual General Meeting and Explanatory Circular to Shareholders 2026	PU
29/04	PureTech Health : Form of Proxy – Annual General Meeting 2026	PU
29/04	PureTech Health : 2025 Annual Report and Accounts (optimized for display)	PU
29/04	PureTech Announces Annual Results for Year Ended December 31, 2025	BU
29/04	PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange	BU
27/04	PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors	BU
23/04	PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed, Refractory High-Risk Myelodysplastic Syndrome and R/R Acute Myeloid Leukemia	AQ
22/04	PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)	BU
13/04	PureTech Health: Notice of Results	BU
02/04	PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine	BU
02/04	PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers	BU
26/03	PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300)	AQ
25/03	PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans	BU